IP Library Granted Patent US 12,569,477
Granted Patent B2
US 12,569,477 · App. 18/091,167 · Granted Mar 10, 2026

Compositions for synergistically enhancing mitochondrial function

Inventors: Larisa Andreeva (London, GB); Igor Anatolievich Pomytkin (Moscow, RU); Galina Nonina Skladtchikova (Hellemp, DK)
Assignee: MITOCHOLINE LTD
A61K31/455A23L33/13A23L33/15A23L33/17A61K31/194A61K31/197A61K31/706A61K47/16A61P25/24A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,569,477
App. No.
18/091,167
Granted
Mar 10, 2026
Kind
B2
Abstract

Methods and compositions for reducing symptoms of mental concentration dysfunction, mood dysfunction, and/or stress-related dysfunction. In various examples, the methods include selecting a subject experiencing a symptom of mental concentration dysfunction, mood dysfunction, and/or stress-related dysfunction and providing for consumption by the subject, a nicotinamide composition formulated to reduce a frequency and/or severity of the symptom. The nicotinamide composition includes a first component and a second component. In some examples, the first component includes nicotinamide (NAM), nicotinamide riboside, or nicotinamide mononucleotide and the second component includes one or more compounds that provide a choline cation and a succinate anion (2−). In certain examples, the molar ratio of the choline cation:succinate anion (2−):first component is between 2:1:0.01 and 2:1:1.

Claims (22)

1 . A composition comprising:

nicotinamide (NAM);

creatine or a creatine precursor selected from glycine and arginine; and

choline cation and a succinate anion (2−),

wherein a molar ratio between the nicotinamide, choline cation and succinate anion (2−) in the composition is between 0.1:2:1 and 1:2:1, correspondingly.

2 . The composition of claim 1 , wherein the composition comprises dicholine succinate (DiSu).

3 . A dietary supplement for a human subject comprising an effective amount of a composition comprising:

nicotinamide (NAM); and

choline cation and succinate anion (2−),

wherein a molar ratio between the nicotinamide, choline cation and succinate anion (2−) in the composition is between 0.1:2:1 and 1:2:1, correspondingly; and the effective amount comprises 10-1000 mg nicotinamide per serving.

4 . The dietary supplement of claim 3 , wherein the composition comprises dicholine succinate (DiSu).

5 . The dietary supplement of claim 4 , wherein the composition further comprises creatine or a creatine precursor selected from glycine and arginine.

6 . A composition comprising:

a nicotinamide compound selected from nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN); and

choline cation and succinate anion (2−),

wherein a molar ratio between the nicotinamide compound, choline cation, and succinate anion (2−) in the composition is between 0.1:2:1 and 1:2:1, correspondingly.

7 . The composition of claim 6 , wherein the composition comprises dicholine succinate (DiSu).

8 . The composition of claim 7 , wherein the composition further comprises creatine or a creatine precursor selected from glycine and arginine.

9 . The composition of claim 8 , wherein the nicotinamide compound comprises nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN).

10 . The composition of claim 8 , wherein the composition is formulated as a beverage.

11 . The composition of claim 10 , wherein the beverage comprises 10-1000 mg of the nicotinamide compound per serving.

12 . The composition of claim 8 , wherein the composition is formulated as a dietary supplement.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS FOR THE APPLICANT WHICH NEEDS TO BE UPDATED PREVIOUSLY RECORDED ON REEL 65960 FRAME 118. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded Mar 13, 2026
From: ANDREEVA, LARISA; POMYTKIN, IGOR ANATOLIEVICH; SKLADTCHIKOVA, GALINA NONINA
To: MITOCHOLINE LTD.
Reel/Frame 075092/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2023
From: ANDREEVA, LARISA; POMYTKIN, IGOR ANATOLIEVICH; SKLADTCHIKOVA, GALINA NONINA
To: MITOCHOLINE LTD.
Reel/Frame 065960/0118 →
Priority Claims (4)
GB 1710316 · Jun 28, 2017 · national
GB 1715214 · Sep 20, 2017 · national
GB 1800244 · Jan 8, 2018 · national
GB 1807733 · May 12, 2018 · national
Continuity (3)
Continuation In Part 18051460 · Oct 31, 2022
Continuation 16624830
Related Publication 20230181557A1 · Jun 15, 2023
References Cited (41)
US 3579423A · Yamane et al. · 1971 [cited by applicant]
US 7666908B2 · Pomytkin et al. · 2010 [cited by applicant]
US 8367121B2 · Mazzio et al. · 2013 [cited by applicant]
US 8673977B2 · Pomytkin · 2014 [cited by applicant]
US 11571415B2 · Andreeva · 2023 [cited by examiner]
US 11826362B2 · Andreeva · 2023 [cited by examiner]
US 20060199862A1 · Pomytkin · 2006 [cited by examiner]
US 20090214680A1 · Giuliano et al. · 2009 [cited by applicant]
US 20090258001A1 · Ponath · 2009 [cited by examiner]
US 20150374745A1 · Pomytkin et al. · 2015 [cited by applicant]
WO 2009022933A1 · 2009 [cited by applicant]
McCandless, Cerebral Energy Metabolism and Metabolic Encephalopathy, 1985, pp. 313-329. [cited by examiner]
AK Reeve et al., “Aggregated a-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons”, Cell Death and Disease (2015) 6, e1820; doi:10.1038/cddis.2015.166, Jul. 16, 2015, pp. 1-1… [cited by applicant]
S. Ogoh et al, “Cerebral blood flow during exercise: mechanisms of regulation”, J Appl Physiol 107:. Sep. 3, 2009, pp. 1370-1380. [cited by applicant]
B. Hassel et al., “Cerebral dicarboxylate transport and metabolism studied with isotopically labelled fumarate, malate and malonate”, Journal of Neurochemistry, 2002, pp. 410-419. [cited by applicant]
SH Zeisel et al., “Choline: An Essential Nutrient for Public Health”, Nutr Rev. Author manuscript; available in PMC, Nov. 25, 2009, pp. 1-14. [cited by applicant]
MJ Valenzuela et al., “Complex mental activity and the aging brain: Molecular, cellular and cortical network mechanisms”, ScienceDirect, Brian Reserch Reviews, 2007, pp. 198-213. [cited by applicant]
ZI Storozjeva et al., “Dicholine salt of succinic acid, a neuronal insulin sensitizer, ameliorates cognitive deficits in rodent models of normal aging, chronic cerebral hypoperfusion, and beta-amyloid peptide-(25-35)-in… [cited by applicant]
T. Wallimann et al., “Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the ‘phosphocreatine circuit’ for cellular energy homeostas… [cited by applicant]
XH. Zhu et al., “In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences”, PNAS vol. 122 No. 9, Mar. 3, 2015, pp. 2876-2881. [cited by applicant]
F. Bartolome et al., “Measurement of Mitochondrial NADH and FAD Autofl uorescence in Live Cells”, Mitochondrial Medicine: vol. I, Probing Mitochondrial Function, 2015, pp. 263-270. [cited by applicant]
LD. Lukyanova et al., “Mitochondria-controlled signaling mechanisms of brain protection in hypoxia”, Frontiers in Nueroscience, Oct. 1, 2015, pp. 1-15. [cited by applicant]
X. Chen et al., “Molecular and functional analysis of SDCT2, a novel rat sodium-dependent dicarboxylate transporter”. The Journal of Clinical Investigation vol. 103, No. 8, Apr. 1999, pp. 1159-1168. [cited by applicant]
V. Knott et al., “Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers”, ScienceDirect, Pharmacology, Biochemistry and Behavior, Feb. 12, 2015, pp. 119-129. [cited by applicant]
PK.Shetty et al., “Nicotinamide pre-treatment ameliorates NAD(H) hyperoxidation and improves neuronal function after severe hypoxia”, Neurobiol Dis Vo. 62, Feb. 2014, pp. 1-21. [cited by applicant]
B. Gong et al., “Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receprot-y coactivator 1a regulated B-secretase 1 degradation and mitochondrial gene expression in Alzheimer's … [cited by applicant]
A. Vaarmann et al., “Novel pathway for an old neurotransmitter: Dopamine-induced neuronal calcium signalling via receptor-independent mechanisms”, ScienceDirect, Cell Calcium vol. 48, Sep. 16, 2010, pp. 176-182. [cited by applicant]
C. Rae et al., “Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial”, The Royal Society, Aug. 13, 2003, pp. 2147-2150. [cited by applicant]
AP. Wojtovich et al., “Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel”, Biochim Biophys Acta, NIH Public Access, May 1, 2014, pp. 1-32. [cited by applicant]
PC. Hinkle, “P/O ratios of mitochondrial oxidative phosphorylation”, ScienceDirect, Biochimica et Biophysica Acta, Sep. 2004, pp. 1-11. [cited by applicant]
IA. Pomytkin et al., “Study of the Effect of Preconditioning with Succinic Acid Salt of Choline (1:2) on the Disturbances of Energy Metabolism in the Brain during Ischemia by 31 P NMR In vivo”, Doklady Biochemistry and … [cited by applicant]
BH. Cline et al., “The neuronal insulin sensitizer dicholine succinate reduces stress-induced depressive traits and memory deficit: possible role of insulin-like growth factor 2”, BMC Neuroscience, 2002, pp. 1-14. [cited by applicant]
H. Imamura et al, “Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators”, PNAS vol. 106 No. 37, Sep. 15, 2009, pp. 15651-15656. [cited by applicant]
“WHO Model List of Essential Medicines” 19th Edition, Apr. 2015, pp. 1-51 (55). [cited by applicant]
M. Gerlach et al., Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases?, Journal of Neurochemistry vol. 63, No. 3, 1994, pp. 793-807. [cited by applicant]
D. Kapogiannis et al., “Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease”, Lancet Neurology vol. 10, Feb. 2011, pp. 187-198. [cited by applicant]
McCandless et al., “Cerebral Energy Metabolism and Metabolic Encephalopathy”, Departments of Anesthesia and Physiology, The Milton S. Hershey Medical Center, The Pennsylvania State University College of Medicine, Hershe… [cited by applicant]
M. Hargreaves et al., “Skeletal muscle energy metabolism during exercise” Nature Metabolism vol. 2, Sep. 2020, pp. 817-828. [cited by applicant]
A. Leyssens et al., “The relationship between mitochondrial state, ATP hydrolysis, [Mg2+]i and [Ca2+]i studied in Isolated rat cardiomyocytes”, The Journal of Physiology, 496.1, Oct. 1, 1996, pp. 111-128. [cited by applicant]
A. Moretti et al., “Choline: An Essential Nutrient for Skeletal Muscle”, Nutrients, MDPI, Jul. 18, 2020, pp. 1-11. [cited by applicant]
A. Reddy et al., “pH-Gated Succinate Secretion Regulates Muscle Remodeling in Response to Exercise”, Cell vol. 183 Issue 1, Oct. 1, 2020, pp. 62-75. [cited by applicant]